AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 289: E1007-E1014, 2005. First published July 19, 2005; doi:10.1152/ajpendo.00109.2005
0193-1849/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/6/E1007    most recent
00109.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granado, M.
Right arrow Articles by López-Calderón, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granado, M.
Right arrow Articles by López-Calderón, A.

Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle

Miriam Granado,1 Teresa Priego,1 Ana I. Martín,2 Mª Ángeles Villanúa,1 and Asunción López-Calderón1

1Facultad de Medicina, Departamento Fisiología, Universidad Complutense y 2Departamento Ciencias Morfológicas y Fisiología, Universidad Europea, Madrid, Spain

Submitted 11 March 2005 ; accepted in final form 14 July 2005

Chronic arthritis is a catabolic state associated with an inhibition of the IGF system and a decrease in body weight. Cachexia and muscular wasting is secondary to protein degradation by the ubiquitin-proteasome pathway. The aim of this work was to analyze the effect of adjuvant-induced arthritis on the muscle-specific ubiquitin ligases muscle ring finger 1 (MuRF1) and muscle atrophy F-box (MAFbx) as well as on IGF-I and IGF-binding protein-5 (IGFBP-5) gene expression in the skeletal muscle. We also studied whether the synthetic ghrelin receptor agonist, growth hormone releasing peptide-2 (GHRP-2), was able to prevent arthritis-induced changes in the skeletal muscle. Arthritis induced an increase in MuRF1, MAFbx (P < 0.01), and tumor necrosis factor (TNF)-{alpha} mRNA (P < 0.05) in the skeletal muscle. Arthritis decreased the serum IGF-I and its gene expression in the liver (P < 0.01), whereas it increased IGF-I and IGFBP-5 gene expression in the skeletal muscle (P < 0.01). Administration of GHRP-2 for 8 days prevented the arthritis-induced increase in muscular MuRF1, MAFbx, and TNF-{alpha} gene expression. GHRP-2 treatment increased the serum concentrations of IGF-I and the IGF-I mRNA in the liver and in the cardiac muscle and decreased muscular IGFBP-5 mRNA both in control and in arthritic rats (P < 0.05). GHRP-2 treatment increased muscular IGF-I mRNA in control rats (P < 0.01), but it did not modify the muscular IGF-I gene expression in arthritic rats. These data indicate that arthritis induces an increase in the activity of the ubiquitin-proteasome proteolytic pathway that is prevented by GHRP-2 administration. The parallel changes in muscular IGFBP-5 and TNF-{alpha} gene expression with the ubiquitin ligases suggest that they can participate in skeletal muscle alterations during chronic arthritis.

growth hormone-releasing peptide-2; atrogenes; insulin-like growth factor I; insulin-like growth factor-binding protein-5; tumor necrosis factor; arthritic rats



Address for reprint requests and other correspondence: A. López-Calderón, Dept Fisiología, Fac Medicina, Univ Complutense, 28040, Madrid (e-mail: ALC{at}med.ucm.es)




This article has been cited by other articles:


Home page
J EndocrinolHome page
A I Martin, E Castillero, M Granado, M Lopez-Menduina, M A Villanua, and A Lopez-Calderon
Adipose tissue loss in adjuvant arthritis is associated with a decrease in lipogenesis, but not with an increase in lipolysis
J. Endocrinol., April 1, 2008; 197(1): 111 - 119.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Granado, A. I. Martin, M. Lopez-Menduina, A. Lopez-Calderon, and M. A. Villanua
GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia
Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E131 - E141.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. Granado, A. I Martin, M{a} A. Villanua, and A. Lopez-Calderon
Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1656 - E1665.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
N. Filigheddu, V. F. Gnocchi, M. Coscia, M. Cappelli, P. E. Porporato, R. Taulli, S. Traini, G. Baldanzi, F. Chianale, S. Cutrupi, et al.
Ghrelin and Des-Acyl Ghrelin Promote Differentiation and Fusion of C2C12 Skeletal Muscle Cells
Mol. Biol. Cell, March 1, 2007; 18(3): 986 - 994.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.